SW
CHRS icon

SteelPeak Wealth’s Coherus Oncology CHRS Stock Holding History

SteelPeak Wealth’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$14.3K – 396
2022
Q4 		– Hold
0
– – – 405

Other funds holding CHRS

PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

SteelPeak Wealth's CHRS Position: Q2 2026 in Review

SteelPeak Wealth held its Coherus Oncology (CHRS) position steady in Q2 2026 at 69,000 shares worth $96.6K. The position accounts for ﹤0.01% of the portfolio, ranked #623.

SteelPeak Wealth first reported a position in CHRS in Q4 2022 and has held it in 15 quarters since. The position peaked at $230K in Q4 2023. 9 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • SteelPeak Wealth held 69,000 shares of Coherus Oncology worth $96.6K as of Q2 2026.
  • SteelPeak Wealth left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of SteelPeak Wealth's portfolio in Q2 2026, its #623 holding.
  • SteelPeak Wealth first reported a position in Coherus Oncology in Q4 2022 and has held it in 15 quarters since.
  • SteelPeak Wealth's Coherus Oncology position peaked at $230K in Q4 2023.
  • 9 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.